Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report

Yoko Noda, MDa, Toru Miyoshi MDa,b, Hiroki Oe, MDc, Yuko Ohno, MTb, Kazufumi Nakamura, MDb, Norihisa Toh, MDb, Kunihiisa Kohno, MDb, Hiroshi Morita, MDa,b, Kengo Kusano, MDb, Hiroshi Ito, MDb

aDepartment of Cardiovascular Medicine and bDepartment of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

cCenter of Ultrasonic Diagnostics, Okayama University Hospital, Okayama, JAPAN

Corresponding author: Toru Miyoshi MD, PhD

Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Okayama 700-8558, Japan
Tel.: 81 86 235 7351; Fax: 81 86 222 7353; E-mail: miyoshit@cc.okayama-u.ac.jp
Abstract

**Background:** Postprandial hyperlipidemia impairs endothelial function and participates in the development of atherosclerosis. We investigated the postprandial effects of a dipeptidyl peptidase IV inhibitor, alogliptin, on endothelial dysfunction and the lipid profile.

**Methods:** A randomized cross-over trial design in 10 healthy volunteers (8 males and 2 females, 35 ± 10 years) was performed. The postprandial effects before and after a 1-week treatment of 25 mg/day alogliptin on endothelial function were assessed with brachial artery flow-mediated dilation (FMD) and changing levels of lipids, apolipoprotein B48 (apoB-48), glucose, glucagon, insulin, and glucagon-like peptide-1 (GLP-1) during fasting and at 2, 4, 6, and 8 h after a standard meal loading test.

**Results:** Alogliptin treatment significantly suppressed the postprandial elevation in serum triglyceride (incremental area under the curve [AUC]; 279 ± 31 vs. 182 ± 32 mg h/dl, p = 0.01), apoB-48 (incremental AUC; 15.4 ± 1.7 vs. 11.7 ± 1.1 μg h/ml, p = 0.04), and remnant lipoprotein cholesterol (RLP-C) (incremental AUC: 29.3 ± 3.2 vs. 17.6 ± 3.3 mg h/dl, p = 0.01). GLP-1 secretion was significantly increased after alogliptin treatment. Postprandial endothelial dysfunction (maximum decrease in %FMD, from −4.2 ± 0.5% to −2.6 ± 0.4%, p = 0.03) was significantly associated with the maximum change in apoB-48 (r = −0.46, p = 0.03) and RLP-C (r = −0.45, p = 0.04).

**Conclusion:** Alogliptin significantly improved postprandial endothelial dysfunction and postprandial lipemia, suggesting that alogliptin may be a promising anti-atherogenic agent.

**Key words:** Dipeptidyl peptidase IV inhibitor; postprandial lipid; triglyceride-rich lipoprotein, endothelial dysfunction; alogliptin
1. Introduction

Large prospective studies have shown that non-fasting postprandial triglyceride (TG) concentrations predict cardiovascular risk better than fasting TG concentrations and that this relationship is independent of traditional coronary risk factors [1, 2]. TG-rich lipoproteins, which consist of chylomicrons assembled by TG, dietary cholesterol, and apolipoprotein B-48 (apoB-48), are highly atherogenic and contribute to the development of coronary heart disease. Thus, the increased risk of cardiovascular events associated with non-fasting TG concentrations may reflect atherogenic properties of TG-rich lipoproteins generated during the postprandial period [3]. Studies have shown that postprandial lipemia contributes to the production of proinflammatory cytokines and oxidative stress, resulting in endothelial dysfunction even in healthy normolipidemic people [4, 5]. Furthermore, other studies demonstrated that postprandial hyperlipemia caused by oral fat intake impairs endothelial dysfunction as detected with flow-mediated dilatation (FMD) of the brachial artery in healthy volunteers. This endothelial dysfunction is associated with postprandial TG-rich lipoproteins [6, 7]. Therefore, identification of novel therapeutic approaches that would beneficially affect postprandial concentrations of lipids is of great interest.

Alogliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4) and has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes, presumably by inhibiting the inactivation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulino tropic polypeptide (GIP), thereby improving islet function [8-10]. Recent clinical studies have reported that DPP-4 inhibitors such as vildagliptin and sitagliptin improve postprandial atherogenic TG-rich lipoprotein levels in patients with type 2 diabetes [11, 12]. However, the effects of other DPP-4 inhibitors on postprandial lipemia-induced endothelial
dysfunction have not been fully evaluated.

The aim of this study was to investigate the effects of alogliptin on postprandial triglyceride (TG)-rich lipoprotein and postprandial lipemia-induced endothelial dysfunction.
2. Methods

2.1. Participants

Ten volunteers, including eight men and two women, were recruited. The study consisted of two 1-week cross-over treatment periods with 25 mg/day alogliptin and placebo in random order, including a 1-week washout period between the two phases. All participants underwent medical check-ups. None of the 10 volunteers had hypertension, impaired glucose tolerance, dyslipidemia, or cerebrovascular or cardiovascular disease, but three volunteers were current smokers. Family histories were obtained from medical interviews. Impaired glucose tolerance was defined as 2-h glucose level of 140–199 mg/dl after the meal loading test [13], and dyslipidemia was defined as one or more of the following criteria at the fasting state: (1) serum triglyceride ≥150 mg/dL, (2) HDL-cholesterol <40 mg/dL, and (3) LDL-cholesterol ≥140 mg/dL [14]. Lipid profiles and endothelial function, which was assessed with brachial artery FMD during fasting and at 2, 4, 6, and 8 h after an oral cookie loading test, were determined following each phase of treatment. Participants were instructed to take one tablet after their morning meal. This study was approved by the Ethics Committee of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, and written informed consent was obtained from all volunteers before beginning the protocol.

2.2. Study protocol

After overnight fasting for at least 8 h, a cookie test was performed. The cookie consisted of 75 g carbohydrate (flour starch and maltose), 28.5 g fat (butter), and 8 g protein for a total of 592 kcal per a carton (SARAYA Corp., Osaka, Japan) [15]. Participants were instructed to ingest the cookie with water within 20 min. Time measurement was started when half the cookie had been ingested. Venous blood samples were drawn, and endothelium-dependent vascular function, as
assessed with FMD of the brachial artery, was determined during the fasting state before cookie ingestion and at 2, 4, 6, and 8 h after the cookie load. Endothelium-independent dilation, as assessed with nitroglycerin-mediated dilation (NMD), was also measured during fasting before cookie ingestion and 8 h after the cookie load. For the 8 h after eating the cookie, the participants were instructed not to eat anything else. Measurements of FMD and NMD were performed by the same technician, who was blinded to the study design and medication status.

2.3. Measurement of biochemical parameters

The following parameters during fasting before cookie ingestion were measured: serum total cholesterol (Total-C), TG, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), remnant lipoprotein cholesterol (RLP-C), apoB-48, adiponectin, soluble vascular cell adhesion molecule 1 (VCAM-1), and plasma glucose levels. HbA1c levels were measured using high-performance liquid chromatography. Concentrations of fasting plasma insulin were measured using a chemiluminescent enzyme immunoassay. Lipid profiles and other markers were measured at SRL Co., Ltd., Tokyo, Japan. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as \[\text{fasting plasma glucose (mg/dl)} \times \text{fasting plasma insulin (μIU/ml)/405}\]. Serum Total-C, TG, LDL-C, HDL-C, RLP-C, apoB-48, plasma glucose, and soluble VCAM-1 were measured at 2, 4, 6, and 8 h after the cookie load. To compare the postprandial changes in these parameters before and after treatment for 4 weeks, the area under the curve (AUC) was calculated using the trapezoidal method.

2.4. FMD measurement

Endothelium-dependent and -independent dilation was assessed as a parameter of vasodilation according to the guidelines for ultrasound assessment of FMD of the brachial artery [16]. Using a 10-MHz linear-array transducer probe (Unex Company Ltd., Nagoya, Japan),
longitudinal images of the brachial artery at baseline were recorded with a stereotactic arm, and measurements of artery diameter were made after supine rest for ≥5 min. The diameter of the artery was measured from clear anterior (media-adventitia) and posterior (intima-media) interfaces, which were manually determined. Then, suprasystolic compression (50 mmHg higher than systolic blood pressure) was performed at the right forearm for 5 min, and measurements of artery diameter were made continuously from 30 s before to ≥2 min after cuff release. After ≥10 min of rest from FMD measurement, artery diameter at baseline and for 5 min after administration of 0.3 mg sublingual nitroglycerin was also measured. Maximum vasodilation was then evaluated from the change in artery diameter after release of occlusion (%FMD) and after administration of nitroglycerin (%NMD).

2.5. Statistical analysis

Sample size was determined based on the estimated FMD reported in another recent study [7]. We assumed that the mean improvement in postprandial %FMD was 2.7% and the standard deviation (SD) was 2.0%. To use a two-sided test for differences, a minimal sample size of 10 participants was required in each group to detect statistical differences in %FMD with a power of 80% and an α-type error of 5% in statistical analysis. Results and data in the figures are expressed as the mean ± standard error (SE). Categorical variables were compared using the χ² test or Fisher's exact test. Differences in lipid profile and endothelial function between the two groups were compared using the Wilcoxon signed-ranks test. Pearson correlation coefficients were used to assess the relationships between maximum reduction in postprandial %FMD and lipid profiles. Values of p < 0.05 were considered significant.
3. Results

3.1. Characteristics of participants

The mean age and body mass index of these volunteers were 35 ± 10 years and 23.9 ± 4.1 kg/m², respectively. Participants maintained their weight throughout the study. Table 1 shows the lipid/lipoprotein profile and the glycemic parameters of the participants following each 1-week phase of either control or treatment with 25 mg/day alogliptin. During fasting, 1-week treatment with alogliptin did not affect the lipid/lipoprotein profile or the levels of adiponectin and soluble VCAM-1. Alogliptin significantly increased GLP-1 levels with no significant impact on fasting blood glucose or HOMA-IR (insulin resistance). No significant differences were observed in systolic and diastolic blood pressure following alogliptin treatment.

3.2. Postprandial lipid and glucose homeostasis

The levels of lipid/lipoprotein, parameters of glucose homeostasis, and soluble VCAM-1 in the postprandial state are shown in Fig. 1 and Supplementary Table 1 (see supplementary data). The serial changes in parameters following each 1-week phase of either control or treatment with alogliptin are shown in Fig. 1. In the control group, the postprandial levels of serum TG, RLP-C, apoB-48, and GLP-1 increased and peaked at 2 or 4 h and then returned to baseline at 8 h. The levels of glucose, total-C, LDL-C, HDL-C, and soluble VCAM-1 did not change significantly during the postprandial state. Therefore, the nominal maximum changes and the incremental AUCs of TG, RLP-C, ApoB-48, glucose, and GLP-1 were calculated. The total AUCs of total-C, LDL-C, HDL-C, glucagon, and soluble VCAM-1 were also calculated for comparison.

The maximum changes in postprandial TG, RLP-C, ApoB-48, and GLP-1 were significantly smaller in the alogliptin group compared with the control group (Table 2). The incremental AUCs of serum TG, RLP-C, and apoB-48 were significantly lower in the alogliptin group than in the
control group (incremental AUC of TG: 279 ± 31 mg vs. 182 ± 32 mg h/dl, p = 0.01; RLP-C: 29.3 ± 3.2 vs. 17.6 ± 3.3 mg h/dl, p = 0.01; apoB-48: 15.4 ± 1.7 vs. 11.7 ± 1.1 μg h/ml, p = 0.04). No differences in the total AUCs of total-C, LDL-C, or HDL-C were observed between the alogliptin group and the control groups (total AUC of total-C: 1452 ± 252 vs. 1489 ± 248 mg h/dl, p = 0.68, LDL-C: 814 ± 228 vs. 819 ± 218 mg h/dl, p = 0.72, HDL-C: 514 ± 71 vs. 532 ± 79 mg h/dl, p = 0.10).

Regarding parameters of glucose homeostasis, there were no significant differences in the incremental AUCs of glucose or insulin between the alogliptin and control groups (incremental AUC of glucose: 78 ± 15 vs. 77 ± 8 mg h/dl, p = 0.58, insulin: 48.3 ± 10.9 vs. 49.4 ± 14.7, p = 0.96), although the incremental AUC of GLP-1 was increased in the alogliptin group (33.8 ± 5.2 vs. 18.2 ± 4.4 pmol h/l, p = 0.02). The total AUC of glucagon was decreased significantly after alogliptin treatment (451.9 ± 21.9 vs. 515.6 ± 30.4 pg h/ml, p = 0.02). No significant difference was observed in the level of soluble VCAM-1 between the alogliptin and control groups (4931 ± 1528 vs. 4935 ± 1411 ng h/ml, p = 0.79).

3.3. Postprandial endothelial function

Comparison of postprandial endothelial function, which was assessed as %FMD, between the control and alogliptin groups is shown in Fig. 2. In the control group, postprandial %FMD decreased significantly, reached the lowest level at 4 h (from 11.8 ± 0.6 to 7.7 ± 0.3%, fasting vs. 4 h, p < 0.01), and recovered at 8 h (from 11.8 ± 0.6 to 12.3 ± 0.5%, fasting vs. 8 h, p = 0.15). The maximum decrease in postprandial %FMD was significantly improved after alogliptin treatment compared to the control group (−2.6% vs. −4.2%, p = 0.03). In the analysis of all data using the control and alogliptin groups, linear regression analysis revealed that the maximum reduction in postprandial %FMD was significantly associated with maximum increases in
postprandial TG, RLP-C, and apoB-48 concentrations (TG: $r = -0.45$, $p = 0.04$; RLP-C: $r = -0.45$, $p = 0.04$; apoB-48: $r = -0.47$, $p = 0.03$), and tended to be correlated with the maximum change in GLP-1 ($r = 0.39$, $p = 0.08$). However, the maximum reduction in postprandial %FMD was not associated with the maximum change in postprandial LDL-C, HDL-C, glucose, or soluble VCAM-1.
4. Discussion

This study demonstrated that alogliptin treatment significantly reduced postprandial levels of intestinally derived apo-B48–containing lipoproteins, which were induced by a conventional oral cookie loading test (28.5 g fat per person), and that alogliptin improved postprandial lipemia-induced endothelial dysfunction. Considering the significant association between the beneficial change in endothelial dysfunction and the decrease in TG-rich lipoproteins, cardiovascular risk, especially associated with postprandial lipemia, may be reduced with long-term treatment with alogliptin.

Our study with the oral cookie test showed that a greater increase in TG-rich lipoprotein, but not glucose, was correlated with postprandial FMD impairment in healthy volunteers. Our study did not include people with impaired glucose tolerance and dyslipidemia. Our finding suggests that the impairment in endothelial dysfunction induced by postprandial lipemia is more common than that induced by postprandial hyperglycemia in the general population. As reported in other studies, postprandial hyperglycemia induces endothelial dysfunction, especially in patients with diabetes mellitus or glucose intolerance. In these patients, an increase in glucose is also associated with postprandial endothelial dysfunction [17]. Furthermore, patients with diabetes mellitus often show dyslipidemia including postprandial hyperlipemia. Therefore, our results suggest that alogliptin therapy possibly improves glucose metabolism as well as postprandial hyperlipemia and postprandial endothelial dysfunction in patients with diabetes mellitus.

Previous studies showed that DPP-4 inhibitors such as vildagliptin and sitagliptin decrease postprandial TG, RLP-C, and apoB-48 levels after a fat-loading test in patients with type 2 diabetes [11, 12]; however, our study is the first to show that alogliptin reduces the postprandial increase in triglyceride-rich lipoproteins in non-obese nondiabetic subjects.
This study was not designed to examine the molecular mechanisms underlying the effect of alogliptin on postprandial hyperlipemia, but several mechanisms are possible. A study showed that GLP-1 influences intestinal TG absorption [18], potentially by inhibiting gastric lipase [19]. Animal studies have shown that DPP-4 inhibition or GLP-1 receptor agonists significantly reduce intestinal secretion of TG, cholesterol, and apoB-48, suggesting that GLP-1 may directly regulate lipoprotein assembly or the secretion in enterocytes [20]. As shown in our previous study, administration of ezetimibe, an inhibitor of cholesterol absorption, improves postprandial lipemia-induced endothelial dysfunction, mainly due to suppression of postprandial TG-rich lipoproteins [7]. In our current study, the maximum decrease in FMD was significantly associated with the maximum change in TG, RLP-C, and apoB-48, but not glucose. Although further studies are needed to determine the extent to which decreased TG absorption and increased chylomicron clearance contribute to the alogliptin-induced reduction in postprandial lipid response, these findings support our concept that alogliptin markedly decreases the levels of postprandial TG-rich lipoproteins, resulting in prevention of postprandial lipemia-induced endothelial dysfunction.

Regarding another proposed mechanism of improvement in postprandial endothelial dysfunction, an increase in active GLP-1 after alogliptin administration may have direct favorable effects on vascular function. An experimental study reported that sitagliptin improves endothelial function and reduces proinflammatory cytokines and atherosclerosis in apoE-deficient mice [21]. Another experimental study showed that a GLP-1 analog reduces oxidative stress in endothelial cells [22]. A clinical study showed that vildagliptin improves endothelium-dependent vasodilatation as determined by plethysmography in patients with type 2 diabetes in a fasting state [23]. Postprandial inflammation and oxidative stress, which are well known to affect the
metabolism of nitric oxide and the release of vasoconstrictive mediators, result in endothelial
dysfunction [5, 24]. In our study, we did not examine the effect of alogliptin on postprandial
oxidative stress. We evaluated the levels of soluble VCAM-1 as a marker of vascular
inflammation, but no significant difference was observed. Therefore, we cannot conclude whether
the administration of alogliptin improves postprandial inflammation and oxidative stress. A
previous study compared the effects of α-glucosidase inhibitors on postprandial glucose/lipid
metabolism and endothelial dysfunction in patients with diabetes and showed that miglitol was
better than voglibose regarding a greater reduction in triglyceride and a greater induction of
GLP-1 [25]. In addition, another study showed that a single dose of exenatide improves
postprandial endothelial dysfunction in individuals with impaired glucose tolerance and
recent-onset type 2 diabetes. These clinical studies indicate that GLP-1 has direct favorable
effects on postprandial endothelial dysfunction [26]. In our current study, no difference was
observed between the alogliptin and control groups in glucose levels at 2 h, which was probably
due to our use of healthy volunteers. Even though we did not compare alogliptin and other
glycemic control agents in this study, a greater spike in GLP-1 after the fat-loading test and/or a
greater secretion of GLP-1 after each meal for 1 week in the alogliptin group may have partly
contributed to the protective effect on postprandial endothelial dysfunction.

A clinical report showed that sitagliptin treatment for 3 months increases adiponectin levels
in patients with diabetes mellitus [27]. This report also suggests that improvement of endothelial
function by sitagliptin therapy is associated with the change in adiponectin. An experimental
study also showed that sitagliptin significantly increases circulating levels of adiponectin in
OLETF rats [28]. Adiponectin has vasoprotective effects via regulation of endothelial nitric oxide
synthase in vascular endothelial cells. Even though our study failed to show a significant increase
in adiponectin levels after 1 week of treatment with alogliptin—probably owing to short-term administration—the long-term effect of alogliptin therapy on adiponectin levels needs to be elucidated.

There is mixed evidence for the benefits of improved glycemic control on cardiovascular events and mortality in patients with diabetes mellitus. The 10 years of primary follow-up from the landmark UK Prospective Diabetes Study (UKPDS) [29] and three recent outcome studies (the Action to Control Cardiovascular Risk in Diabetes [ACCORD] [30], Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation [ADVANCE] [31], and Veterans Affairs Diabetes Trial [VADT] [32]) all failed to demonstrate that intensive glycemic control reduces cardiovascular events and mortality. In contrast, recent studies showed that a DPP-4 inhibitor may reduce cardiovascular events in patients with diabetes [33]. Experimental studies also showed the favorable action of DPP-4 on vascular cells via a GLP-1-independent mechanism [34]. These data indicate that DPP-4 may have potential for preventing cardiovascular events beyond glycemic control; however, another group reported that vildagliptin has no protective effects on cardiac function in a rat model of post-myocardial infarction heart failure [35]. Thus, the cardiovascular benefits of DPP-4 inhibitors beyond glycemic control should be clarified in a future study.

4.1. Study limitations

There are several important limitations of our study. First, this was an open-label study, and the number of participants enrolled in our study was small. Therefore, a degree of selection bias may have occurred. Second, no widely used method for assessing postprandial hyperlipemia has been established, and so various fat-loading tests, such as oral fat meal, fat cream intake, and intravenous fat load, have been used in previous studies. We used the cookie test, which provided
sufficient information about glucose intolerance and postprandial hyperlipemia [13]. Although the cookie provided a fixed amount of fat (28.5 g) per person, the amount of fat given per body surface area was not the same in this study. Therefore, the contribution of each person’s fat metabolism cannot be ruled out as an influential factor. A meal loading test using 30 g fat/m$^2$ body surface area showed a greater increase in TG and RLP compared with that using a fixed amount of fat (28.5 g) per person, even in healthy volunteers [7]. The effect of alogliptin on postprandial lipemia after the meal loading test with 30 g fat/m$^2$ body surface area would also be informative, especially in patients with diabetes or dyslipidemia.

In conclusion, we demonstrated that inhibition of DPP-4 with alogliptin was effective for reducing postprandial elevation of TG-rich lipoproteins and the accompanying induction of postprandial endothelial dysfunction. Alogliptin may be a useful drug for reducing future cardiovascular disease by ameliorating endothelial dysfunction in the postprandial state, even in low-risk patients.

Conflicts of interest

None.

Acknowledgment

We thank Koaru Akazawa, Masayo Ohmori, and Miyuki Fujiwara for their excellent technical support.

Authors' contributions

YN, TM, JO, KN, conceived the study, and participated in its design and coordination and helped
to draft the manuscript.

YN, TM, YO carried out examinations

NT, KK, HM, KK, HI were involved in drafting the manuscript or revising it critically

All authors read and approved the final manuscript.
Figure legends

Figure 1
The serial change in glucose (A), triglyceride (TG) (B), remnant lipoprotein cholesterol (RLP-C) (C), apolipoprotein B-48 (ApoB-48) (D), glucagon-like peptide-1 (GLP-1) (E), and glucagon (F).
*p<0.05 vs. control group.

Figure 2
The serial change in endothelial function after cookie ingestion in the alogliptin and control groups. FMD, flow-mediated dilation (A), and maximum decrease in the alogliptin and control groups (B).
References

1. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. *JAMA* 2007, **298**(3):309-316.

2. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA* 2007, **298**(3):299-308.

3. Zilversmit DB: Atherogenesis: a postprandial phenomenon. *Circulation* 1979, **60**(3):473-485.

4. Bae JH, Bassenge E, Kim KB, Kim YN, Kim KS, Lee HJ, Moon KC, Lee MS, Park KY, Schwemmer M: Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. *Atherosclerosis* 2001, **155**(2):517-523.

5. van Oostrom AJ, Sijmonsma TP, Verseyden C, Jansen EH, de Koning EJ, Rabelink TJ, Castro Cabezas M: Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. *J Lipid Res* 2003, **44**(3):576-583.

6. Marchesi S, Lupattelli G, Schillaci G, Pirro M, Siepi D, Roscini AR, Pasqualini L, Mannarino E: Impaired flow-mediated vasoactivity during post-prandial phase in young healthy men. *Atherosclerosis* 2000, **153**(2):397-402.

7. Yunoki K, Nakamura K, Miyoshi T, Enko K, Kohno K, Morita H, Kusano KF, Ito H: Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. *Atherosclerosis* 2011, **217**(2):486-491.

8. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate
glycemic control: a randomized, double-blind, placebo-controlled study. *Diabetes care* 2008, 31(12):2315-2317.

9. Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene RJ, Asakawa T, Takeuchi K, Xu R, Webb DR, Gwaltney SL, 2nd: **Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.** *J Med Chem* 2007, 50(10):2297-2300.

10. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H: **Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.** *Eur J Pharmacol* 2008, 588(2-3):325-332.

11. Matikainen N, Manttari S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR: **Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.** *Diabetologia* 2006, 49(9):2049-2057.

12. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P: **Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.** *Diabetes, obesity & metabolism* 2011, 13(4):366-373.

13. American Diabetes Association: **Diagnosis and classification of diabetes mellitus.** *Diabetes Care* 2005, 28 Suppl 1:S37-42.

14. Japan Atherosclerosis Society: **Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases.** *J Atheroscler Thromb* 2007:5-57.

15. Harano Y, Miyawaki T, Nabiki J, Shibachi M, Adachi T, Ikeda M, Ueda F, Nakano T:
Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. *Endocrine journal* 2006, **53**(2):173-180.

16. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R: *Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force*. *J Am Coll Cardiol* 2002, **39**(2):257-265.

17. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H: *Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery*. *J Am Coll Cardiol* 1999, **34**(1):146-154.

18. Qin X, Shen H, Liu M, Yang Q, Zheng S, Sabo M, D'Alessio DA, Tso P: *GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats*. *Am J Physiol Gastrointest Liver Physiol* 2005, **288**(5):G943-949.

19. Wojdemann M, Wettergren A, Sternby B, Holst JJ, Larsen S, Rehfeld JF, Olsen O: *Inhibition of human gastric lipase secretion by glucagon-like peptide-1*. *Dig Dis Sci* 1998, **43**(4):799-805.

20. Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ, Adeli K: *The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice*. *Diabetologia* 2010, **53**(3):552-561.

21. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi...
H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H: A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. *J Am Coll Cardiol* 2012, **59**(3):265-276.

22. Shiraki A, Oyama J, Komoda H, Asaka M, Komatsu A, Sakuma M, Kodama K, Sakamoto Y, Kotooka N, Hirase T, Node K: The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells. *Atherosclerosis* 2012, **221**(2):375-382.

23. van Poppel PC, Netea MG, Smits P, Tack CJ: Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. *Diabetes care* 2011, **34**(9):2072-2077.

24. Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F, Eriksson P, Catapano AL: Post-prandial endothelial dysfunction in hypertriglycerideremic subjects: molecular mechanisms and gene expression studies. *Atherosclerosis* 2007, **193**(2):321-327.

25. Hiki M, Shimada K, Kiyanagi T, Fukao K, Hirose K, Ohsaka H, Fukushima Y, Kume A, Matsumori R, Sumiyoshi K, Miyazaki T, Ohmura H, Kurata T, Miida T, Daida H: Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH). *Circ J* 2010, **74**(7):1471-1478.

26. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD: Improvement of postprandial endothelial function after a single dose of exenatide in individuals with
impaired glucose tolerance and recent-onset type 2 diabetes. *Diabetes Care* 2010, 33(5):1028-1030.

27. Kazunari Suzuki, Kentaro Watanabe, Tatsuya Suzuki, Motoshi Ouchi, Shoko Futami-Suda, Yoshimasa Igari, Hiroshi Nakano, Kenzo Oba: Sitagliptin improves vascular endothelial function in Japanese type 2 diabetes patients without cardiovascular disease. *Journal of Diabetes Mellitus* 2012, 2(3), 338-345 (2012)

28. Lim S, Choi SH, Shin H, Cho BJ, Park HS, Ahn BY, Kang SM, Yoon JW, Jang HC, Kim YB, Park KS: Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. *PLoS One* 2012, 7(4):e35007.

29. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998, 352(9131):837-853.

30. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Jr., Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008, 358(24):2545-2559.

31. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008, 358(24):2560-2572.

32. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J,
Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: **Glucose control and vascular complications in veterans with type 2 diabetes.** *N Engl J Med* 2009, 360(2):129-139.

33. Cobble ME, Frederich R: **Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.** *Cardiovasc Diabetol* 2012, 11:6.

34. Zhong J, Rao X, Rajagopalan S: **An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease.** *Atherosclerosis* 2012.

35. Yin M, Sillje HH, Meissner M, van Gilst WH, de Boer RA: **Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.** *Cardiovasc Diabetol* 2011, 10:85.
**Abbreviations**

apoB-48: apolipoprotein B48  
AUC: area under the curve  
BMI: body mass index  
DPP-4: dipeptidyl peptidase IV  
FMD: flow-mediated dilation  
GIP: glucose-dependent insulinotropic polypeptide  
GLP-1: glucagon-like peptide-1  
HDL-C: high-density lipoprotein cholesterol  
HOMA-IR: homeostasis model assessment of insulin resistance  
LDL-C: low-density lipoprotein cholesterol  
NMD: nitroglycerin-mediated dilation  
RLP-C: remnant lipoprotein cholesterol  
SD: standard deviation  
SE: standard error  
TG: triglyceride  
Total-C: total cholesterol  
VCAM-1: vascular cell adhesion molecule 1
Table 1. Characteristics of participants

|                          | Control (n = 10) | Alogliptin (n = 10) | p value |
|--------------------------|------------------|---------------------|---------|
| Age (years)              | 35 ± 10          | -                   | -       |
| Male (%)                 | 8 (80)           | -                   | -       |
| Current Smoker (%)       | 3(30)            | -                   | -       |
| HbA1c (%)                | 4.6 ± 0.3        | -                   | -       |
| BMI (kg/m²)              | 23.9 ± 4.1       | 23.9 ± 3.4          | 0.86    |
| Systolic blood pressure  | 122 ± 3          | 121 ± 3             | 0.35    |
| Diastolic blood pressure | 71 ± 2           | 71 ± 2              | 0.99    |
| Heart rate (beats/min)   | 62 ± 3           | 61 ± 2              | 0.20    |
| Total-C (mg/dl)          | 185.3 ± 10.6     | 180.7 ± 9.9         | 0.58    |
| LDL-C (mg/dl)            | 103.2 ± 8.9      | 102.2 ± 9.3         | 0.72    |
| HDL-C (mg/dl)            | 66.3 ± 3.1       | 64.2 ± 3.4          | 0.29    |
| TG (mg/dl)               | 73.7 ± 10.2      | 63.4 ± 7.9          | 0.08    |
| RLP-C (mg/dl)            | 8.4 ± 1.2        | 6.7 ± 0.8           | 0.28    |
| ApoB-48 (µg/ml)          | 2.5 ± 0.3        | 2.2 ± 0.2           | 0.19    |
| Glucose (mg/dl)          | 93.0 ± 2.0       | 94.3 ± 2.1          | 0.54    |
| Glucagon (pg/ml)         | 63.5 ± 5.4       | 59.4 ± 2.8          | 0.44    |
| Insulin (µIU/ml)         | 4.8 ± 0.8        | 4.9 ± 1.3           | 0.38    |
| HOMA-IR                  | 1.1 ± 0.2        | 1.1 ± 0.3           | 0.51    |
| GLP-1 (pmol/l)           | 3.2 ± 0.2        | 5.2 ± 0.7           | 0.03    |
| Adiponectin (µg/ml)      | 9.6 ± 0.8        | 9.7 ± 0.7           | 0.31    |
| Soluble VCAM-1 (ng/ml)   | 629 ± 72         | 606 ± 50            | 0.76    |
Data are the mean ± SE or frequency counts (percentages), as appropriate. BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; RLP-C, remnant lipoprotein cholesterol; ApoB-48, apolipoprotein B-48; HOMA-IR, homeostasis model assessment of insulin resistance; GLP-1, glucagon-like peptide-1; VCAM-1, vascular cell adhesion molecule-1.
Table 2. Maximum change in lipids and glucose metabolism in the alogliptin and control groups.

|                  | Control       | Alogliptin    | p   |
|------------------|---------------|---------------|-----|
| TG (mg/dl)       | 59.7 ± 7.8    | 48.3 ± 6.4    | 0.01|
| RLP-C (mg/dl)    | 6.1 ± 0.6     | 4.8 ± 0.7     | 0.02|
| ApoB-48 (μg/ml)  | 4.0 ± 0.4     | 2.8 ± 0.2     | 0.01|
| Glucose (mg/dl)  | 20.5 ± 2.4    | 20.4 ± 3.9    | 0.51|
| Insulin (μIU/ml) | 19.4 ± 6.3    | 18.2 ± 4.8    | 0.87|
| GLP-1 (pmol/l)   | 5.4 ± 1.3     | 10.2 ± 1.3    | 0.04|

Data are the mean ± SE. TG, triglyceride; RLP-C, remnant lipoprotein cholesterol; ApoB-48, apolipoprotein B-48; GLP-1, glucagon-like peptide-1.